{"id":56696,"date":"2026-02-09T22:29:09","date_gmt":"2026-02-09T14:29:09","guid":{"rendered":"https:\/\/flcube.com\/?p=56696"},"modified":"2026-02-09T22:29:11","modified_gmt":"2026-02-09T14:29:11","slug":"delonix-bioworks-dx-104-becomes-first-china-approved-engineered-omv-vaccine-targets-1-3-billion-menb-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56696","title":{"rendered":"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market"},"content":{"rendered":"\n<p><strong>Delonix Bioworks<\/strong> announced that <strong>DX-104<\/strong>, its <strong>Group B meningococcal (MenB) vaccine candidate<\/strong>, has received <strong>clinical trial approval<\/strong> from the <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>NMPA<\/strong>. The <strong>first engineered outer membrane vesicle (OMV) vaccine approved for clinical development in China<\/strong> will enter <strong>Phase I studies in Australia<\/strong> this quarter, leveraging <strong>global data generation<\/strong> to support international regulatory pathways.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Delonix Bioworks (Shanghai-based)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>CDE\/NMPA (China); TGA (Australia \u2013 approved Jan 2026)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>DX-104 \u2013 Group B meningococcal (MenB) vaccine<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Engineered OMV (outer membrane vesicle) vaccine<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Proprietary OMV Plus\u2122 technology<\/td><\/tr><tr><td><strong>China Status<\/strong><\/td><td>First engineered OMV vaccine approved for clinical trials<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Phase I Australia initiation (Q1 2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-competitive-differentiation\">Technology Platform &amp; Competitive Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>DX-104 (Delonix)<\/th><th>Bexsero (GSK)<\/th><th>Strategic Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Technology<\/strong><\/td><td>Engineered OMV Plus\u2122<\/td><td>Native OMV + recombinant proteins<\/td><td>Optimized immunogen presentation<\/td><\/tr><tr><td><strong>Adjuvant Requirement<\/strong><\/td><td><strong>None required<\/strong><\/td><td>Requires adjuvant<\/td><td>Enhanced safety profile; simplified manufacturing<\/td><\/tr><tr><td><strong>Immune Response<\/strong><\/td><td>Strong native OMV immunogenicity<\/td><td>Established efficacy<\/td><td>Potentially superior durability<\/td><\/tr><tr><td><strong>Pyrogenic Reaction<\/strong><\/td><td><strong>Significantly lower<\/strong> than Bexsero<\/td><td>Baseline reactogenicity<\/td><td>Improved tolerability, especially in pediatric populations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence-amp-market-context\">Preclinical Evidence &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>DX-104 Performance<\/th><th>Benchmark (GSK Bexsero)<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>SBA Assays<\/strong> (international licensure endpoint)<\/td><td><strong>Significant superiority<\/strong> vs. prevalent Chinese strains<\/td><td>Current standard<\/td><td>Potential for best-in-class efficacy in Asia-Pacific<\/td><\/tr><tr><td><strong>Pyrogenicity<\/strong><\/td><td>Significantly reduced<\/td><td>Higher baseline<\/td><td>Competitive safety advantage for pediatric and adolescent vaccination<\/td><\/tr><tr><td><strong>Manufacturing<\/strong><\/td><td>Adjuvant-free process<\/td><td>Complex multi-component formulation<\/td><td>Cost and scalability advantages<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Reference:<\/strong> GSK&#8217;s <strong>Bexsero<\/strong> (only commercially available OMV-based MenB vaccine) generated <strong>USD 1.3 billion in 2024 sales<\/strong>, demonstrating <strong>strong commercial traction<\/strong> and <strong>market growth potential<\/strong> for next-generation MenB vaccines.<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> MenB causes <strong>50% of meningococcal disease globally<\/strong> with <strong>high mortality\/morbidity<\/strong>; current vaccine coverage remains limited due to cost, reactogenicity, and strain coverage gaps.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-development-roadway\">Strategic Positioning &amp; Development Roadway<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Execution Plan<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I Australia<\/strong><\/td><td>Safety and immunogenicity in healthy adults<\/td><td>Q1-Q4 2026<\/td><\/tr><tr><td><strong>Global Development<\/strong><\/td><td>Leverage Australia data for US\/EU IND submissions<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Strategic Partnerships<\/strong><\/td><td>Explore Big Pharma licensing for ex-China commercialization<\/td><td>Data-dependent<\/td><\/tr><tr><td><strong>China Registration<\/strong><\/td><td>Parallel Phase I\/II development pathway<\/td><td>Post-Australia data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover China Advantage:<\/strong> As the <strong>first engineered OMV vaccine<\/strong> approved by CDE, DX-104 positions Delonix for <strong>domestic market leadership<\/strong> and <strong>government procurement preference<\/strong> under China&#8217;s vaccine self-sufficiency initiatives.<\/li>\n\n\n\n<li><strong>OMV Platform Validation:<\/strong> DX-104 success validates Delonix&#8217;s <strong>OMV Plus\u2122 platform<\/strong> for <strong>rapid pandemic response<\/strong> and <strong>multivalent vaccine development<\/strong> (e.g., OMV-based COVID-19, influenza candidates).<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding DX-104 clinical development timelines, superiority to Bexsero in Phase I\/II trials, and Delonix Bioworks&#8217; partnership and commercialization strategy. Actual results may differ due to immunogenicity variability in human studies, competitive responses from GSK and Pfizer (MenB vaccines), and global regulatory requirements for novel OMV engineering.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4020,12],"class_list":["post-56696","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-delonix-bioworks","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The first engineered outer membrane vesicle (OMV) vaccine approved for clinical development in China will enter Phase I studies in Australia this quarter, leveraging global data generation to support international regulatory pathways.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56696\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market\" \/>\n<meta property=\"og:description\" content=\"Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The first engineered outer membrane vesicle (OMV) vaccine approved for clinical development in China will enter Phase I studies in Australia this quarter, leveraging global data generation to support international regulatory pathways.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56696\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T14:29:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T14:29:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56696#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56696\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market\",\"datePublished\":\"2026-02-09T14:29:09+00:00\",\"dateModified\":\"2026-02-09T14:29:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56696\"},\"wordCount\":456,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Delonix Bioworks\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56696#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56696\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56696\",\"name\":\"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-09T14:29:09+00:00\",\"dateModified\":\"2026-02-09T14:29:11+00:00\",\"description\":\"Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The first engineered outer membrane vesicle (OMV) vaccine approved for clinical development in China will enter Phase I studies in Australia this quarter, leveraging global data generation to support international regulatory pathways.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56696#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56696\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56696#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market - Insight, China&#039;s Pharmaceutical Industry","description":"Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The first engineered outer membrane vesicle (OMV) vaccine approved for clinical development in China will enter Phase I studies in Australia this quarter, leveraging global data generation to support international regulatory pathways.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56696","og_locale":"en_US","og_type":"article","og_title":"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market","og_description":"Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The first engineered outer membrane vesicle (OMV) vaccine approved for clinical development in China will enter Phase I studies in Australia this quarter, leveraging global data generation to support international regulatory pathways.","og_url":"https:\/\/flcube.com\/?p=56696","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-09T14:29:09+00:00","article_modified_time":"2026-02-09T14:29:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56696#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56696"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market","datePublished":"2026-02-09T14:29:09+00:00","dateModified":"2026-02-09T14:29:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56696"},"wordCount":456,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Delonix Bioworks","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56696#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56696","url":"https:\/\/flcube.com\/?p=56696","name":"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-09T14:29:09+00:00","dateModified":"2026-02-09T14:29:11+00:00","description":"Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China\u2019s NMPA. The first engineered outer membrane vesicle (OMV) vaccine approved for clinical development in China will enter Phase I studies in Australia this quarter, leveraging global data generation to support international regulatory pathways.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56696#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56696"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56696#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Delonix Bioworks\u2019 DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56696"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56696\/revisions"}],"predecessor-version":[{"id":56699,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56696\/revisions\/56699"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}